Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro.
Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro.
复制标题
DOI：
10.1016/j.ijantimicag.2019.08.023
复制
发表时间：
2019-08
影响因子：
10.8
通讯作者：
Jin-Lei Wang;H. Elsheikha;Ting-Ting Li-Ting;Jun-Jun He-Jun;M. Bai;Qin-Li Liang;Xing-Quan Zhu;W. Cong
中科院分区：
文献类型：
--
作者：
Jin-Lei Wang;H. Elsheikha;Ting-Ting Li-Ting;Jun-Jun He-Jun;M. Bai;Qin-Li Liang;Xing-Quan Zhu;W. Cong
专性细胞内寄生虫弓形虫感染几乎所有的温血动物，包括人类。虽然感染这种寄生虫通常是良性的，严重的疾病可能会发生在感染的个人，如果他们的免疫力变得不太称职，如在人类免疫缺陷病毒（HIV）感染patients.In这项研究中，44种常用的抗逆转录病毒化合物的抑制活性测定againstT。离体刚地菌。在44种测试的抗逆转录病毒化合物中，14种显示出抗T的效力。刚地拉的IC_（50）浓度（浓度依赖性T.弓形虫生长50%），范围为1.18 ± 2.21 µM（奈非那韦）至18.89 ± 1.87 µM（曲韦啶）。在14种有效的抗逆转录病毒化合物中，有7种是HIV-1蛋白酶抑制剂。本研究还调查了这14种抗逆转录病毒化合物的联合给药是否会干扰抗T。现有抗T. gondiidrugs，即磺胺嘧啶和乙胺嘧啶。结果表明，14种抗逆转录病毒化合物与乙胺嘧啶或磺胺嘧啶之间没有显著的相互作用。这些结果证明，是否管理的领导抗逆转录病毒药物与高效抗T。对HIV患者的弓形虫感染可能有助于限制弓形虫脑炎的发生。
The obligate intracellular parasiteToxoplasma gondiican infect nearly all warm-blooded animals, including humans. Although infection with this parasite is generally benign, severe illness may occur in infected individuals if their immunity becomes less competent, such as in human immunodeficiency virus (HIV)-infected patients.In this study, the inhibitory activity of 44 commonly used antiretroviral compounds was determined againstT. gondiiin vitro. Of the 44 tested antiretroviral compounds, 14 showed potency againstT. gondiiat IC50concentrations (concentration inhibitingT. gondiitachyzoite growth by 50%) ranging from 1.18 ± 2.21 µM (nelfinavir) to 18.89 ± 1.87 µM (trovirdine). Of the 14 potent antiretroviral compounds, 7 are HIV-1 protease inhibitors. This study also investigated whether co-administration of these 14 antiretroviral compounds interferes with the anti-T. gondiiactivity of existing anti-T. gondiidrugs, namely sulfadiazine and pyrimethamine. The results showed no significant interaction between any of the 14 tested antiretroviral compounds and pyrimethamine or sulfadiazine. These results warrant investigation of whether administration of the lead antiretroviral drugs with highly potent anti-T. gondiiactivity to HIV patients may help to limit the occurrence of toxoplasmic encephalitis.